SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of FAYUVI as the first treatment for Sanfilippo syndrome Type A, along with a Priority Review Voucher, is driving attention and expectations for a commercial launch. Traders are split after the relatively muted share reaction: bulls emphasize the new revenue stream, voucher value and short interest, while skeptics point to the narrow patient population, safety and uptake considerations, and Ultragenyxs cash burn.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that sports-event contracts are sports bets rather than federally protected swaps is drawing attention, as traders view it as a potential regulatory win for DraftKings and a setback for Kalshi-style prediction markets. Debate remains over whether the decision will materially reduce competition, with a possible Supreme Court appeal and DraftKings own prediction-market exposure leaving the longer-term impact uncertain.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Reported insider buying by CEO Ryan Cohen, including a purchase of 1 million shares, is fueling renewed bullish interest in GameStop alongside speculation about additional buybacks. Traders are also debating whether rising call activity, borrow costs and momentum could trigger a short or gamma squeeze, though some remain cautious about the low volume and range-bound price action.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas fully enrolled Phase 3 APPROACH trial for HLP003, with topline major-depressive-disorder data expected in Q4 2026. Traders are citing executive purchases and new CEO Michael Halstead as confidence signals, while others warn that expectations, profit-taking, and potential dilution could drive volatility.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

A sharp post-earnings decline to 52-week lows has focused traders on Dutch Bros premium valuation, consumer-spending concerns, and uncertainty around its proposed acquisition and conversion of former Salad and Go locations. Bulls cite strong growth, store expansion, and busy shops, while bears point to elevated multiples, insider selling, possible dilution, and financing risks.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeonas early commercial rollout of ZEVASKYN is driving attention, with Q2 results showing sequential revenue growth but a shortfall versus expectations after one treatment batch failed to meet the billing threshold. Traders are divided between viewing the manufacturing issue and slow treatment-center ramp as evidence of execution problems and seeing expanding centers, patient demand, and future profitability as intact catalysts.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Attention is centered on Uniswaps Robinhood integration and its role as a liquidity layer for crypto and tokenized-asset trading, with traders linking the development to higher volume, protocol revenue, and fee-driven UNI burns. Bulls view the combination as a structural catalyst, while skeptics point to overbought technical conditions and the risk of a pullback.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

A sharp rally and technical breakout have pushed NEAR into focus, with traders chiefly attributing the move to Zcashs outperformance and a perceived close correlation between the two tokens. The community is broadly bullish and citing NEARs AI/agent-infrastructure narrative, although some traders view the move as a liquidity pump and are positioning for a pullback.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Early clinical data from Biohavens degrader programs in Graves disease and IgA nephropathy are driving attention, with traders highlighting rapid antibody reductions and signs of efficacy while viewing the platform as increasingly validated. The reaction is bullish, though some note the results remain early-stage and the broader pipeline still carries clinical and financing risk.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is drawing attention after a sharp rally and strong relative performance versus major cryptocurrencies, with traders emphasizing its privacy-focused use case, capped supply and possible short liquidations as drivers. Bulls frame it as a Bitcoin 2.0 opportunity, while skeptics warn that FOMO, crowded positioning and overbought conditions could lead to a sharp pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Schrdingers formation of Tectra, contributing two early-stage small-molecule programs in exchange for an ownership stake, milestones and royalties, is the main catalyst traders are citing for the sharp advance. The community is broadly bullish on the capital-light structure and AI-driven drug-discovery theme, while some debate whether the move reflects takeover speculation or short-term momentum and warn the stock may be overbought.

Closing Power Hour: Biotech, AI, Energy and Crypto Stories Take Center Stage

The final stretch of trading is bringing a fresh batch of catalysts across biotech, energy, AI and digital assets, with the following names delivering developments capable of reshaping their narratives. Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), Turbo Energy (NASDAQ:TURB), CID HoldCo (NASDAQ:DAIC), Paradium.AI (NYSE:PAAI), StablecoinX (NASDAQ:USDE), FuelCell Energy (NASDAQ:FCEL), and Schrödinger (NASDAQ:SDGR).

Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrdinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the companys common stock to three newly hired employees. These grants were made pursuant to the companys 2021 Inducement Equity Incentive...

SDGR Crosses Above Average Analyst Target

In recent trading, shares of Schrodinger Inc (Symbol: SDGR) have crossed above the average analyst 12-month target price of $21.43, changing hands for $23.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valu...

Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?

Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033

AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033 AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033PR NewswireAUSTIN, Texas, Sept. 14, 2026 AUSTIN, Texas, Sept. 14, 2026 /PRNewswire/ -- USA News Group News Commentary- Artificial intelligence is moving from the edges...

Schrdinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

Schrdinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million...

Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?

Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.

"Schrodinger's Strait:" Why Hormuz Now Exists in a State of Permanent Uncertainty

"Schrodinger's Strait:" Why Hormuz Now Exists in a State of Permanent Uncertainty...

AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030

AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 PR Newswire AUSTIN, Texas, Sept. 3, 2026 AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt...

Schrdinger to Present at Morgan Stanley Global Healthcare Conference

Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the Investors...

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern

Equity

Extremely Bullish Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits Polls

Strong recent gains have fueled significant hype as traders debate whether to chase the rally or brace for a pullback.

Current Price	$30.24
Prev Close	$23.93
Open	$24.09
Dividend Yield	0.00%
50-Day Moving Average	$17.91
Beta	1.60
Avg. Volume	1.16M
PE Ratio	-32.48

52-Week High	$24.39
52-Week Low	$10.95
Market Capitalization	$1.79B
EPS (Annual)	-$1.41
Price to Book	5.44
Revenue Per Employee	$301,022.35

Feed

News

Sentiment

Earnings

Fundamentals

Info

SDGR Fundamentals